Tenet Healthcare Corp (THC)
割安ファンダメンタル
69
株価
$255.23
時価総額
$20.77B
パート1 · 企業の価値
概要
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; tertiary care services, such as cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; pediatric quaternary care services through heart, liver, and kidney transplants programs; and limb salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging technology, surgical robotic, and telemedicine access services. In addition, it offers a range of procedures and services comprising orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; pain management; otolaryngology; ophthalmology; and urology. Further, the company operates acute care and specialty hospitals, off-campus emergency departments, imaging centers, urgent care centers, and micro-hospitals, as well as ambulatory surgery centers and surgical hospitals. Tenet Healthcare Corporation was founded in 1967 and is headquartered in Dallas, Texas.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$21.81B
直近12か月（2026/6/30まで）
純利益
$3.17B
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$2.53B
自己資本合計
$4.22B
負債合計
$20.70B
流動比率
1.41
利払い倍率
5.54
負債/EBITDA
3.03
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$610.78
現在株価
$255.23
安全マージン
+58.2%
適正価値レンジ
$397.01 - $824.55
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
9.86
ROE
56.1%
P/B レシオ
4.42
P/FCF
6.81
粗利益率
-
ROIC
14.3%
収益性レーダー
価値創造（経済的モート）
ROIC
14.3%
WACC
8.8%
ROIC − WACC
+5.5 pp
ROICが資本コストを上回っています。企業は株主のために価値を創出しています。
ファンダメンタル分析基準
合格（18）
- EPS shows upward trend
- EPS CAGR 40.13%
- Price CAGR 33.35%
- ROIC 14.3%
- P/FCF 6.81
- Operating Margin 20.8%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 50.6%
- Analyst Consensus 85% Buy
- Earnings Surprise avg 20.9%
- PEG Ratio 0.28
- Earnings Quality (OCF/NI) 1.26
- Net Margin Trend 14.6% vs 11.6%
- Piotroski F-Score 5/9
不合格（8）
- P/B Ratio 4.42
- Debt/Equity ratio
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 3.9%
- Share Dilution 23.0%
データなし（2）
- Gross Margin NaN%
- Dividend Payout NaN%
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
新株を発行しており、所有権を希薄化している
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Dr. Saumya Sutaria M.D. | Chairman & CEO | 52 |
| Mr. Sun K. Park | Executive VP & CFO | 49 |
| Ms. Lisa Y. Foo | Executive VP & Chief Operating Officer | 34 |
| Ms. Paola M. Arbour | Executive VP & Chief Information Officer | 61 |
| Mr. Thomas W. Arnst | EVP, Chief Administrative Officer, Chief Risk Officer, General Counsel & Corporate Secretary | 62 |
| Mr. John Michael Grooms | Senior VP, Controller & Principal Accounting Officer | 47 |
| Mr. William McDowell III | Vice President of Investor Relations | - |
| Ms. Jana Durfee | Senior VP & Chief Compliance Officer | - |
| Mr. Michael T. Maloney | Executive Vice President of Corporate Development | - |
| Mr. Clint Hailey | Chief Managed Care Officer & Senior VP | 60 |
監査リスク
4
取締役会リスク
3
報酬リスク
2
株主権利リスク
1
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for THC, sourced from Markets Gazette.
- 2/20/2026POSITIVEThe Analyst Verdict: Tenet Healthcare In The Eyes Of 12 Experts
Recent analyst ratings for Tenet Healthcare (THC) show a predominantly positive sentiment, with multiple experts maintaining or reinstating "Buy" ratings. This suggests a favorable outlook for the stock, based on fundamental analysis or future growth prospects.
via Markets Gazette